Cargando…

MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS

Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommerkamp, Alexander C, Sun, Pengbo, Wefers, Annika K, Ismer, Britta, Schramm, Kathrin, Wittmann, Andrea, Gronych, Jan, Korshunov, Andrey, von Deimling, Andreas, Jäger, Natalie, Pfister, Stefan M, Jones, David T W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715598/
http://dx.doi.org/10.1093/neuonc/noaa222.585
_version_ 1783618993043537920
author Sommerkamp, Alexander C
Sun, Pengbo
Wefers, Annika K
Ismer, Britta
Schramm, Kathrin
Wittmann, Andrea
Gronych, Jan
Korshunov, Andrey
von Deimling, Andreas
Jäger, Natalie
Pfister, Stefan M
Jones, David T W
author_facet Sommerkamp, Alexander C
Sun, Pengbo
Wefers, Annika K
Ismer, Britta
Schramm, Kathrin
Wittmann, Andrea
Gronych, Jan
Korshunov, Andrey
von Deimling, Andreas
Jäger, Natalie
Pfister, Stefan M
Jones, David T W
author_sort Sommerkamp, Alexander C
collection PubMed
description Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorphic xanthoastrocytoma (PXA; WHO grade II) are two pLGG types that can be difficult to distinguish based on histology alone. Even though their clinical course is different, they are often grouped as ‘pLGG’ in clinical trials (and therefore treated similarly). Based on a cohort of 89 human pediatric tumor samples, we show that PAs and PXAs have clearly distinct methylation and transcriptome profiles. The difference in gene expression is mainly caused by cell cycle- and development-associated genes, suggesting a key difference in the regulatory circuits involved in tumor growth. In addition to BRAF V600E, we found NTRK fusions and a previously unknown EGFR:BRAF fusion as mutually exclusive driving events in PXAs. Both tumor types show marked signs of immune cell infiltration, but with significant qualitative differences, which might represent therapeutic vulnerabilities. To pave the way for further research on PA and PXA, we developed corresponding mouse models using the virus-based RCAS system, which allows introduction of an oncogenic driver into immunocompetent mice for molecular and preclinical research. The murine tumors do not only histologically resemble their human counterparts but also show a similar growth behavior. Expression analysis revealed that the murine PXAs have a stronger gene signature of proliferation and immune cell infiltration compared to PAs.
format Online
Article
Text
id pubmed-7715598
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77155982020-12-09 MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS Sommerkamp, Alexander C Sun, Pengbo Wefers, Annika K Ismer, Britta Schramm, Kathrin Wittmann, Andrea Gronych, Jan Korshunov, Andrey von Deimling, Andreas Jäger, Natalie Pfister, Stefan M Jones, David T W Neuro Oncol Preclinical Models/Experimental Therapy/Drug Discovery Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorphic xanthoastrocytoma (PXA; WHO grade II) are two pLGG types that can be difficult to distinguish based on histology alone. Even though their clinical course is different, they are often grouped as ‘pLGG’ in clinical trials (and therefore treated similarly). Based on a cohort of 89 human pediatric tumor samples, we show that PAs and PXAs have clearly distinct methylation and transcriptome profiles. The difference in gene expression is mainly caused by cell cycle- and development-associated genes, suggesting a key difference in the regulatory circuits involved in tumor growth. In addition to BRAF V600E, we found NTRK fusions and a previously unknown EGFR:BRAF fusion as mutually exclusive driving events in PXAs. Both tumor types show marked signs of immune cell infiltration, but with significant qualitative differences, which might represent therapeutic vulnerabilities. To pave the way for further research on PA and PXA, we developed corresponding mouse models using the virus-based RCAS system, which allows introduction of an oncogenic driver into immunocompetent mice for molecular and preclinical research. The murine tumors do not only histologically resemble their human counterparts but also show a similar growth behavior. Expression analysis revealed that the murine PXAs have a stronger gene signature of proliferation and immune cell infiltration compared to PAs. Oxford University Press 2020-12-04 /pmc/articles/PMC7715598/ http://dx.doi.org/10.1093/neuonc/noaa222.585 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Preclinical Models/Experimental Therapy/Drug Discovery
Sommerkamp, Alexander C
Sun, Pengbo
Wefers, Annika K
Ismer, Britta
Schramm, Kathrin
Wittmann, Andrea
Gronych, Jan
Korshunov, Andrey
von Deimling, Andreas
Jäger, Natalie
Pfister, Stefan M
Jones, David T W
MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title_full MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title_fullStr MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title_full_unstemmed MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title_short MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
title_sort modl-11. comparison of human & murine pa/pxa characteristics
topic Preclinical Models/Experimental Therapy/Drug Discovery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715598/
http://dx.doi.org/10.1093/neuonc/noaa222.585
work_keys_str_mv AT sommerkampalexanderc modl11comparisonofhumanmurinepapxacharacteristics
AT sunpengbo modl11comparisonofhumanmurinepapxacharacteristics
AT wefersannikak modl11comparisonofhumanmurinepapxacharacteristics
AT ismerbritta modl11comparisonofhumanmurinepapxacharacteristics
AT schrammkathrin modl11comparisonofhumanmurinepapxacharacteristics
AT wittmannandrea modl11comparisonofhumanmurinepapxacharacteristics
AT gronychjan modl11comparisonofhumanmurinepapxacharacteristics
AT korshunovandrey modl11comparisonofhumanmurinepapxacharacteristics
AT vondeimlingandreas modl11comparisonofhumanmurinepapxacharacteristics
AT jagernatalie modl11comparisonofhumanmurinepapxacharacteristics
AT pfisterstefanm modl11comparisonofhumanmurinepapxacharacteristics
AT jonesdavidtw modl11comparisonofhumanmurinepapxacharacteristics